The Bakersfield Californian12d
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and ...
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in North America and ...
WJBF20d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti ...
Law20d
Navigating the Complexities of Interrelated Claim Disputes
for documents related to Alexion’s foreign and domestic grant-making activities, Foreign Corrupt Practices Act (FCPA) compliance and statements concerning the recall of a drug called Soliris.
Investing25d
Dianthus Therapeutics announces board changes
King brings over 25 years of experience in biotechnology, notably leading the commercial launch of Soliris® for generalized Myasthenia Gravis (gMG) at Alexion Pharmaceuticals (NASDAQ:ALXN).
contemporarypediatrics27d
FDA expands use of eculizumab to patients 6 years and up with generalized myasthenia gravis
The indicated, FDA-approved use for eculizumab (Soliris; Alexion and AstraZeneca) has been expanded to include pediatric patients aged 6 years and older with generalized myasthenia gravis (gMG) who ...